• Post-Doctoral Research Fellow: Tumor dormancy, metastasis, and immunology

    Job ID
    Regular Full-Time
    Fred Hutchinson Cancer Research Center
    Post-Doctoral Research Fellows and Associates
  • Overview

    Cures Start Here. At Fred Hutchinson Cancer Research Center, home to three Nobel laureates, interdisciplinary teams of world-renowned scientists seek new and innovative ways to prevent, diagnose and treat cancer, HIV/AIDS and other life-threatening diseases. Fred Hutch’s pioneering work in bone marrow transplantation led to the development of immunotherapy, which harnesses the power of the immune system to treat cancer. An independent, nonprofit research institute based in Seattle, Fred Hutch houses the nation’s first cancer prevention research program, as well as the clinical coordinating center of the Women’s Health Initiative and the international headquarters of the HIV Vaccine Trials Network. Careers Start Here.


    A laboratory in Fred Hutchinson Cancer Research Center’s Translational Research Program (Public Health Sciences Division) is looking for a highly motivated Postdoctoral Research Fellow. The candidate would join the Laboratory for the Study of Metastatic Microenvironments (LSM2), directed by Cyrus Ghajar. The LSM2 focuses on understanding the biology underlying disseminated tumor cell (DTC) dormancy (see: Carlson et al., Nature Cell Biology 2019; Goddard et al., Nature Cell Biology 2018; Ghajar et al., Nature Cell Biology 2013) and uncovering means to eradicate dormant DTCs. Our overarching goal is to develop therapeutically viable approaches to prevent breast cancer metastasis.  


    The candidate will spearhead a project with the goals of:

    • Determining whether T cell-based immunotherapies can be used to target dormant DTCs
    • Understanding whether engineered T cell phenotypes/activity are dependent on tissue site
    • Identifying potential DTC-specific antigens/neoantigens from patient specimens.

    The ideal candidate will be interested and able to develop his/her own research strategy to understand DTC-immune cell interactions by utilizing an array of innovative models and sophisticated techniques we have developed or adopted in the lab. These include three-dimensional/organotypic cell culture models, murine metastasis models and intravital imaging approaches. 


    A Ph.D. focusing on immunology or tumor immunology is required. A strong publication record and eligibility and desire to apply for future fellowships are also required. The candidate must also be experienced in essential techniques to characterize and profile immune cells and to gauge their function. A candidate with experience in live cell imaging, bioinformatics, and/or experience working in murine tumor or metastasis models is strongly desired.


    The successful candidate must have excellent communication and organizational skills, the ability to develop creative approaches to experimental design, and thrive both in independent research and while working collaboratively.

    Our Commitment to Diversity

    We are proud to be an Equal Employment Opportunity (EEO) and Vietnam Era Veterans Readjustment Assistance Act (VEVRAA) Employer. We are committed to cultivating a workplace in which diverse perspectives and experiences are welcomed and respected. We do not discriminate on the basis of race, color, religion, creed, ancestry, national origin, sex, age, disability (physical or mental), marital or veteran status, genetic information, sexual orientation, gender identity, political ideology, or membership in any other legally protected class. We are an Affirmative Action employer. We encourage individuals with diverse backgrounds to apply and desire priority referrals of protected veterans. If due to a disability you need assistance/and or a reasonable accommodation during the application or recruiting process, please send a request to our Employee Services Center at escmail@fredhutch.org or by calling 206-667-4700.


    Sorry the Share function is not working properly at this moment. Please refresh the page and try again later.
    Share on your newsfeed